We are live on ! Find out more
IGC icon

IGC Pharma
IGC

28 hedge funds and large institutions have $929K invested in IGC Pharma in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

14% more capital invested

Capital invested by funds: $815K → $929K (+$114K)

12% more funds holding

Funds holding: 25 → 28 (+3)

0.22% more ownership

Funds ownership: 3.59% → 3.81% (+0.22%)

Holders
28
Holders Change
+3
Holders Change %
+12%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$53K
2
Renaissance Technologies
Renaissance Technologies
New York
+$16.5K
3
VF
Virtu Financial
New York
+$14.1K
4
UBS Group
UBS Group
Switzerland
+$10.9K
5
Jane Street
Jane Street
New York
+$4K

Top Sellers

Rank Fund Capital Flow
1
Squarepoint
Squarepoint
New York
-$40K
2
XT
XTX Topco
Cayman Islands
-$5.5K
3
State Street
State Street
Massachusetts
-$1.53K
4
TRCT
Tower Research Capital (TRC)
New York
-$437
5
Simplex Trading
Simplex Trading
Illinois
-$30

IGC Hedge Fund Activity: Q2 2025 in Review

28 of the 7,610 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2025, worth a combined $929K — up 14% from $815K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IGC positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $53K. The largest seller was Squarepoint, exiting entirely with an estimated $40K sold.

  • 28 institutional investors held IGC Pharma (IGC) as of Q2 2025, up from 25 in Q1 2025.
  • Funds reported $929K of IGC Pharma stock for Q2 2025, up 14% quarter-over-quarter.
  • 5 funds opened new IGC Pharma positions in Q2 2025 and 2 closed out, a net change of +3 holders.
  • The largest IGC Pharma buyer in Q2 2025 was Citadel Advisors, an estimated $53K added.
  • The largest IGC Pharma seller in Q2 2025 was Squarepoint, an estimated $40K sold.

Based on aggregated 13F filings for Q2 2025.